HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy

Journal of Molecular Medicine

Volumn 89, Issue 12, 2011, Pages 1231-1240

  Zizzari, Ilaria Grazia ^a   Veglia, Filippo ^a   Taurino, Federica ^a   Rahimi, Hassan ^a   Quaglino, Elena ^b   Belleudi, Francesca ^a   Riccardo, Federica ^b   Antonilli, Morena ^a   Napoletano, Chiara ^a   Bellati, Filippo ^a   Benedetti Panici, Pierluigi ^a   Torrisi, Maria Rosaria ^a   Frati, Luigi ^c,d   Nuti, Marianna ^a,d   Rughetti, Aurelia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Antigen processing; Cancer immunotherapy; Dendritic cell targeting; Dendritic cells; Fc R; HER2

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 FC RECEPTOR FUSION PROTEIN; FC RECEPTOR; GAMMA INTERFERON; HUMAN IMMUNOGLOBULIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN CROSS LINKING;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84655161589     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0794-7     Document Type: Article

References (32)

1. K Palucka J Banchereau I Mellman 2010 Designing vaccines based on biology of human dendritic cell subsets Immunity 33 464 478 21029958 10.1016/j.immuni.2010.10.007 1:CAS:528:DC%2BC3cXhtlGmtLvL
2. B Pulendran 2005 Variegation of the immune response with dendritic cells and pathogen recognition receptors J Immunol 174 2457 2465 15728447 1:CAS:528:DC%2BD2MXhsFerur4%3D (Pubitemid 40279654)
3. PJ Tacken IJ de Vries R Torensma CG Figdor 2007 Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Nat Rev Immunol 7 790 802 17853902 10.1038/nri2173 1:CAS:528:DC%2BD2sXhtVOrtbjL (Pubitemid 47480309)
4. F Nimmerjahn JV Ravetch 2008 Fcgamma receptors as regulators of immune responses Nat Rev Immunol 8 34 47 18064051 10.1038/nri2206 1:CAS:528: DC%2BD2sXhsVKrsLnK
5. DH Schuurhuis A Ioan-Facsinay B Nagelkerken JJ van Schip C Sedlik CJ Melief JS Verbeek F Ossendorp 2002 Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo J Immunol 168 2240 2246 11859111 1:CAS:528:DC%2BD38XhvVegsr0%3D (Pubitemid 34171824)
6. E Gilboa 2007 DC-based cancer vaccines J Clin Invest 117 1195 1203 17476349 10.1172/JCI31205 1:CAS:528:DC%2BD2sXlt1Omtrc%3D (Pubitemid 46718404)
7. DH Schuurhuis N van Montfoort A Ioan Facsinay R Jiawan M Camps J Nouta CJ Melief JS Verbeek F Ossendorp 2006 Immune complex loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine J Immunol 176 4573 4580 16585547 1:CAS:528:DC%2BD28XjtV2gsrs%3D
8. PS Kim TD Armstrong H Song ME Wolpoe V Weiss EA Manning LQ Huang S Murata G Sgouros LA Emens 2008 Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs J Clin Invest 118 1700 1711 18398507 10.1172/JCI34333 1:CAS:528: DC%2BD1cXlsF2ntLs%3D (Pubitemid 351632374)
9. Z You X Huang J Hester HC Toh SY Chen 2001 Targeting dendritic cells to enhance DNA vaccine potency Cancer Res 61 3704 3711 11325842 1:CAS:528:DC%2BD3MXjsFCgur0%3D (Pubitemid 32694983)
10. DB Lowe MH Shearer CA Jumper RK Bright RC Kennedy 2007 Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases J Virol 81 1313 1318 17108042 10.1128/JVI.01943-06 1:CAS:528:DC%2BD2sXhtFCgu70%3D (Pubitemid 46167852)
11. N Hollander 2009 Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma Crit Rev Immunol 29 399 418 20001888 1:CAS:528:DC%2BC3cXhsFCit7c%3D
12. MZ Ladjemi W Jacot T Chardès A Pèlegrin I Navarro-Teulon 2010 Anti-HER2 vaccines: new prospects for breast cancer therapy Cancer Immunol Immunother 59 1295 1312 20532501 10.1007/s00262-010-0869-2 1:CAS:528: DC%2BC3cXotVOlurk%3D
13. GE Peoples JM Gurney MT Hueman MM Woll GB Ryan CE Storrer C Fisher CD Shriver CG Ioannides S Ponniah 2005 Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients J Clin Oncol 23 7536 7545 16157940 10.1200/JCO.2005.03.047 1:CAS:528:DC%2BD2MXht1Wrsr3M (Pubitemid 46291817)
14. E Quaglino C Mastini A Amici C Marchini M Iezzi S Lanzardo C De Giovanni M Montani PL Lollini G Masucci, et al. 2010 A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins Cancer Res. 70 7 2604 12 20332241 10.1158/0008-5472.CAN-09-2548 1:CAS:528:DC%2BC3cXktFynsLY%3D
15. C Mastini PD Becker M Iezzi C Curcio P Musiani G Forni F Cavallo CA Guzman 2008 Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice Curr Cancer Drug Targets 8 230 42 18473736 10.2174/156800908784293604 1:CAS:528:DC%2BD1cXmtFamtL4%3D (Pubitemid 351666859)
16. C Napoletano D Pinto F Bellati F Taurino H Rahimi F Tomao PB Panici A Rughetti L Frati M Nuti 2007 A comparative analysis of serum and serum-free media for generation of clinical grade DCs J Immunother 30 567 576 17589298 10.1097/CJI.0b013e318046f396
17. HG Rammensee T Friede S Stevanoviíc 1995 MHC ligands and peptide motifs: first listing Immunogenetics 41 178 228 7890324 10.1007/BF00172063 1:CAS:528:DyaK2MXlvVemu7g%3D
18. AO Hovden S Appel 2010 The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA Scand J Immunol 72 554 21044130 10.1111/j.1365-3083.2010.02464.x
19. W Sun H Qian X Zhang C Zhou X Liang D Wang M Fu W Ma S Zhang C Lin 2006 Induction of protective and therapeutic antitumour immunity using a novel tumour-associated antigen-specific DNA vaccine Immunol Cell Biol 84 440 447 16942487 10.1111/j.1440-1711.2006.01453.x 1:CAS:528:DC%2BD28XhtVyis77L (Pubitemid 44286037)
20. M Wang Z Xie M Shi H Lu M Yu M Hu F Lu Y Ma B Shen N Guo 2008 A new strategy to induce effective antitumour response in vitro and in vivo Scand J Immunol 68 287 296 18782257 10.1111/j.1365-3083.2008.02140.x 1:CAS:528:DC%2BD1cXhtFajtrnL
21. G Mariani A Fasolo E De Benedictis L Gianni 2009 Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer Nat Clin Pract Oncol 6 93 104 19107109 10.1038/ncponc1298 1:CAS:528:DC%2BD1MXhtFOmtb0%3D
22. YJ Bang E Van Cutsem A Feyereislova HC Chung L Shen A Sawaki F Lordick A Ohtsu Y Omuro T Satoh ToGa Trial Investigators, et al. 2010 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687 697 20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO
23. EA Mittendorf JP Holmes S Ponniah GE Peoples 2008 The E75 HER2/neu peptide vaccine Cancer Immunol Immunother 57 1511 1521 18536917 10.1007/s00262-008-0540-3 1:CAS:528:DC%2BD1cXovFyisbY%3D
24. S Vertuani A Sette J Sidney S Southwood J Fikes E Keogh JA Lindencrona G Ishioka J Levitskaya R Kiessling 2004 Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues J Immunol 172 3501 3508 15004150 1:CAS:528:DC%2BD2cXhvVKjtL0%3D (Pubitemid 38337930)
25. J Eyles AL Puaux X Wang B Toh C Prakash M Hong TG Tan L Zheng LC Ong Y Jin 2010 Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma J Clin Invest 120 2030 2039 20501944 10.1172/JCI42002 1:CAS:528:DC%2BC3cXnt1KqtLY%3D
26. MD Vesely MH Kershaw RD Schreiber M Smyth 2011 Natural innate and adaptive immunity to cancer Ann Rev Immunol 29 235 71 10.1146/annurev-immunol- 031210-101324 1:CAS:528:DC%2BC3MXltlKns7s%3D
27. EM Hiltbold AM Vlad P Ciborowski SC Watkins OJ Finn 2000 The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells J Immunol 165 3730 3741 11034378 1:CAS:528:DC%2BD3cXntVyisrk%3D (Pubitemid 32057279)
28. C Napoletano A Rughetti MP Agervig Tarp J Coleman EP Bennett G Picco P Sale K Denda-Nagai T Irimura U Mandel, et al. 2007 Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells Cancer Res 67 8358 8367 17804752 10.1158/0008-5472.CAN-07-1035 1:CAS:528: DC%2BD2sXpvFKisr4%3D (Pubitemid 47395175)
29. Y Ma O Kepp F Ghiringhelli L Apetoh L Aymeric C Locher A Tesniere I Martins A Ly NM Haynes, et al. 2010 Chemotherapy and radiotherapy: cryptic anticancer vaccines Semin Immunol 22 113 124 20403709 10.1016/j.smim.2010.03.001
30. C Napoletano F Bellati R Landi S Pauselli C Marchetti V Visconti P Sale M Liberati A Rughetti L Frati, et al. 2010 Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression J Cell Mol Med 14 2748 2759 19780872 10.1111/j.1582-4934.2009.00911.x 1:CAS:528: DC%2BC3MXhtlagu7o%3D
31. CJ Melief SH van der Burg 2008 Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nat Rev Cancer 8 351 360 18418403 10.1038/nrc2373 1:CAS:528:DC%2BD1cXltVGlur0%3D (Pubitemid 351589701)
32. JO Richards S Karki GA Lazar H Chen W Dang JR Desjarlais 2008 Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells Mol Cancer Ther 7 2517 2527 18723496 10.1158/1535-7163.MCT-08- 0201 1:CAS:528:DC%2BD1cXhtVWksLzJ